RSS

cancer

Morphogenesis — Florida-based immunotherapy company — and the Cell and Gene Therapy Group at Karolinska Institutet (KI) in Sweden have announced a collaboration for the development of targeted immunotherapies to treat cancer. more

News

According to a new study, led by the University of Eastern Finland, there is much more variation in cancer-causing KRAS mutations than originally believed. more

News

Biopharmaceutical company, Secarna Pharmaceuticals, has entered into a co-development agreement with research and development company, Firebrand Therapeutics, for novel cancer therapies. more

News

NHS England has announced a landmark deal, giving children and young people access to Novartis’ Kymriah (a chimeric antigen receptor T-cell, CAR-T, therapy) — a personalised therapy for the treatment of cancer. more

News

A synthetic chemical (KHS101) has been discovered by researchers that has the ability to kill aggressive brain tumour cells by removing their source of energy. more

News

Digital Innovations Hubs are to be created in the UK to help connect data and fast-track treatments for a range of important diseases like cancer, heart disease and asthma. more

News

Kite and Gadeta have entered into a strategic collaboration for the development of novel gamma delta T cell receptor (TCR) therapies in various cancers. more

News

Clinical-stage biopharmaceutical company, Immatics Biotechnologies, has entered into a research collaboration and licence agreement with international biotech company, Genmab, to develop next generation bispecific cancer immunotherapies. more

News

A new company that focuses on the development of oncology medicines in Asia, AUM Biosciences (AUM), has officially launched with millions in Singapore dollars of seed funding. more

News

Here, Steve Lyon, digital lead, Communities & Content, Allied Market Research (AMR), discusses some examples of new technology in the ADC space and the ground-breaking potential this new class of drugs will have in the treatment of cancer more

Opinion

Nanobiotix, a late clinical-stage nanomedicine company, has launched a research collaboration with Weill Cornell Medicine to begin nonclinical studies evaluating the impact of NBTXR3 on cGAS-STING pathway in mammary cancers. more

News

Cancer immune-oncology company, NeoPhore, and developer of a next-generation phenotypic screening platform, PhoreMost, have been granted funding from Innovate UK in support of the development of novel small-molecule cancer immunotherapy programme. more

News

A collaboration between IONTAS, a company focused on the discovery and optimisation of fully human antibodies, and IGEM Therapeutics, an immunologist-oncology company, for the identification of novel IgE antibodies for cancer targets. more

News

Boehringer Ingelheim and Vanderbilt University have expanded their partnership to develop novel anti-cancer drugs that inhibit the myeloid cell leukaemia 1 (MCL1) protein, which is highly prevalent in many difficult to treat cancers. more

News

A consortium has been launched by Certara for the development of a quantitative systems pharmacology immune-oncology simulator to test combination cancer therapies and different dose regimens and biomarkers in computer-generated, virtual patients more

News

A drug that specifically targets tropomyosin receptor kinases (TRK) fused genes, larotrectinib, has been found to be effective in patients of all ages, according to recently published results from combined analysis. more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

NHS funded initiative, SBRI Healthcare, has revealed its latest round of development awards, with 10 companies set to share a £1 million investment to develop innovations for high potential cancer screening solutions. more

News

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more

News

The US Food and Drug Administration (FDA) has approved a treatment for a type of cancer that affects the pancreas or gastrointestinal tract — gastroenteropancreatic neuroendocrine tumors (GEP-NETs). more

News